E3泛素连接酶Herc1调节急性髓系白血病对核苷类似物的反应
该研究利用全基因组CRISPR药物基因组学筛选,在KMT2A/MLLT3融合或Hoxa9与Meis1共表达的鼠AML模型中鉴定出E3泛素连接酶Herc1是阿糖胞苷反应的关键调节因子;HERC1缺失通过影响细胞周期进程增强核苷类似物诱导的细胞死亡,脱氧胞苷激酶被鉴定为Herc1的新靶点;HERC1在AML中过表达且高表达与TCGA和BEAT-AML队列中患者总生存期缩短相关。
要点
- 全基因组CRISPR筛选鉴定Herc1为AML中阿糖胞苷反应的关键调节因子
- HERC1缺失通过损害细胞周期进程增强鼠和人类AML细胞系中核苷类似物诱导的细胞死亡
- 脱氧胞苷激酶被鉴定为Herc1在小鼠AML模型中的新靶点
核心结论
- 本研究强调HERC1在AML细胞对核苷类似物反应中的重要性,将这一E3泛素连接酶确立为AML治疗的新型预测生物标志物和潜在治疗靶点。
研究设计与样本
- 研究采用全基因组CRISPR药物基因组学筛选,在由KMT2A/MLLT3融合或Hoxa9与Meis1组成性共表达驱动的鼠AML模型中,于体外和体内鉴定调节核苷类似物反应的遗传因子。
主要发现
- HERC1缺失通过损害细胞周期进程增强鼠和人类AML细胞系中核苷类似物诱导的细胞死亡。
- 深度蛋白质组学分析及后续验证鉴定脱氧胞苷激酶为Herc1在两个小鼠AML模型中的新靶点。
- HERC1在AML中较其他癌症类型过表达,且较高的HERC1表达与TCGA和BEAT-AML队列中AML患者较短的总生存期相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
For several decades, induction therapy with nucleoside analogs, in particular cytarabine (Ara-C) and, to a lesser extent, fludarabine, has been the standard of care for patients diagnosed with acute myeloid leukemia (AML). However, the antitumor efficacy of nucleoside analogs is often limited by intrinsic and acquired drug resistance, thereby leading to poor therapeutic response and suboptimal clinical outcomes. In this study, we used genome-wide CRISPR-based pharmacogenomic screening to map the genetic factors that modulate the response to nucleoside analogs in AML and identified the E3 ubiquitin ligase, Herc1, as a key modulator of Ara-C response in mouse AML models driven by the KMT2A/MLLT3 fusion or by the constitutive coexpression of Hoxa9 and Meis1, both in vitro and in vivo. Loss of HERC1 enhanced nucleoside analog-induced cell death in both murine and human AML cell lines by compromising cell cycle progression. In-depth proteomic analysis and subsequent validation identified deoxycytidine kinase as a novel target of Herc1 in both mouse AML models. We observed that HERC1 is overexpressed in AML when compared with other cancer types and that higher HERC1 expression was associated with shorter overall survival in patients with AML in the The Cancer Gene Atlas program (TCGA) and BEAT-AML cohorts. Collectively, this study highlights the importance of HERC1 in the response of AML cells to nucleoside analogs, thereby establishing this E3 ubiquitin ligase as a novel predictive biomarker and potential therapeutic target for the treatment of AML.
引用
- Jankovic M, Poon WWL, Gonzales-Losada C, et al. The E3 ubiquitin ligase Herc1 modulates the response to nucleoside analogs in acute myeloid leukemia. Blood Adv. 2024. PMID: 39093953. doi:10.1182/bloodadvances.2023011540
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。